Comparison of Intratesticular Testosterone between Men Receiving Nasal, Intramuscular, and Subcutaneous Pellet Testosterone Therapy: Evaluation of Data from Two Single-Center Randomized Clinical Trials

Diaz, Parris; Reddy, Rohit; Blachman‐Braun, Ruben; Zucker, Isaac; Dullea, Alexandra; González, Daniel; Kresch, Eliyahu

doi:10.5534/wjmh.210261

Cited by 5 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in that study, Gn levels were tested once at study entry and again after 90 days [33]. 17-hydroxyprogesterone (17-OHP) circulating levels were taken as a surrogate marker for intratesticular T [35] in a recent two -center randomized study comparing T administration in 75 hypogonadal men (T <10.4 nmol/L) through subcutaneous pellet (TP; 800 mg), T cypionate (TC; 200 mg x 2 weeks), or NT (11 mg t.i.d) for 16 weeks [36]. The three treatment arms reached comparable levels of circulating T, whereas the 4month change in 17-OHP in the NT group (−33.3% from baseline) was less than the change seen in TC (−65.3% from baseline) or TP (−44% from baseline), suggesting a lower effect on intra-testicular T. However, it should be clarified that a consistent portion of the circulating 17-OHP in men is derived from the adrenal gland and therefore does not fully represent the testicular source.…”

Section: Possible Solutions With Available or In Development T Prepar...mentioning

confidence: 99%

Developments and challenges for new and emergent preparations for male hypogonadism treatment

Corona,

Sparano,

Rastrelli

et al. 2023

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Introduction:The specific role of testosterone (T) replacement therapy in patients with late onset hypogonadism is still conflicting. Several available preparations have been developed to restore either fertility and normal testosterone (T) levels (secondary hypogonadism) or just T levels (primary hypogonadism). Areas covered: Advantages and limitations related to available new treatments will be discussed in detail. In addition, possible news related to preparations in the pipeline will be discussed. Expert opinion:The selection of a specific T preparation should be adequately discussed with each subject. Transdermal T preparations are those that can preserve, after a unique morning administration, the circadian rhythmicity of T secretion. Conversely, short-acting preparations (such as oral or intranasal) need two-or threetimes daily administration, potentially reducing patient compliance. Long acting T preparations, such as injectable T undecanoate have the advantage of bimestrial or trimestral administration, reducing the required number of administrations. The use of non-steroidal selective androgen receptor modulators (SARM), a heterogeneous class of compounds selectively acting on androgen receptor targets, remains investigational due to the lack of the full spectrum of T's action and the possible risk of side effects, despite their potential use in the treatment of muscle wasting and osteoporosis.

show abstract

Section: Possible Solutions With Available or In Development T Prepar...mentioning

confidence: 99%